Compare TPCS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | RNXT |
|---|---|---|
| Founded | 1956 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9M | 36.4M |
| IPO Year | N/A | 2021 |
| Metric | TPCS | RNXT |
|---|---|---|
| Price | $4.68 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 29.4K | ★ 185.9K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,564,000.00 | $928,000.00 |
| Revenue This Year | N/A | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.15 | N/A |
| 52 Week Low | $2.05 | $0.70 |
| 52 Week High | $6.25 | $1.69 |
| Indicator | TPCS | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 54.23 | 46.89 |
| Support Level | $4.24 | $0.89 |
| Resistance Level | $4.74 | $1.00 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 76.14 | 38.53 |
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.